Communiqué de presse
Revue 2024 des hypothèses L&H achevée, ratio de solvabilité Groupe de 203 %
3711
-
-
Articles d'expertsnovembre 12, 2024
How consumer groups, patient representatives, and the insurance industry are working in partnership to help protect cancer survivors
-
-
Articles d'expertsoctobre 31, 2024
Using Pandemic Mortality Experience for Pricing Longevity
-
Actualitésoctobre 25, 2024
Winner of the 2024 Most Innovative Product/Service Award - General Insurance
-
Drugs developed for the treatment of diabetes such as semaglutide (marketed as Ozempic or Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro or Zepbound) are being used to decrease the weight of obesity risks:
-
-
-
-
Communiqué de presse
-
Communiqué de presse
À la suite de cette acquisition, SCOR a l'intention de déposer une offre publique d'achat simplifiée
-
Actualitésoctobre 3, 2024
State-of-the-art machine learning engine provides risk scoring for underwriting and claims
